BIOMAT Database Logo BIOMAT Database Logo

Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. 2004

Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan. kitayama-1SU@h.u-tokyo.ac.jp

BACKGROUND Lysophosphatidic acid (LPA) is a bioactive phospholipid with diverse effects on various cells. It interacts with at least three G-protein-coupled transmembrane receptors, namely LPA1, LPA2 and LPA3, whose expression in various tumours has not been fully characterized. In the present study we characterized the expression profile of LPA receptors in human breast cancer tissue and assessed the possible roles of each receptor. METHODS The relative expression levels of each receptor's mRNA against beta-actin mRNA was examined in surgically resected invasive ductal carcinomas and normal gland tissue using real-time RT-PCR. LPA2 expression was also examined immunohistochemically using a rat anti-LPA2 monoclonal antibody. RESULTS In 25 cases normal and cancer tissue contained LPA1 mRNA at similar levels, whereas the expression level of LPA2 mRNA was significantly increased in cancer tissue as compared with its normal counterpart (3479.0 +/- 426.6 versus 1287.3 +/- 466.8; P < 0.05). LPA3 was weakly expressed in both cancer and normal gland tissue. In 48 (57%) out of 84 cases, enhanced expression of LPA2 protein was confirmed in carcinoma cells as compared with normal mammary epithelium by immunohistochemistry. Over-expression of LPA2 was detected in 17 (45%) out of 38 premenopausal women, as compared with 31 (67%) out of 46 postmenopausal women, and the difference was statistically significant (P < 0.05). CONCLUSIONS These findings suggest that upregulation of LPA2 may play a role in carcinogenesis, particularly in postmenopausal breast cancer.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D049368 Receptors, Lysophosphatidic Acid A subfamily of lysophospholipid receptors with specificity for LYSOPHOSPHATIDIC ACIDS. LPA Receptor,Lysophosphatidic Acid Receptor,Lysophosphatidic Acid Receptors,EDG7 Protein,Edg-4 Receptor,Edg-7 Receptor,Edg2 Protein,Edg4 Protein,LPA Receptors,LPA-1 Receptor,LPA1 Receptor,LPA2 Receptor,LPA3 Receptor,Receptor, Lysophosphatidic Acid,edg-2 Receptor,vzg-1 Receptor,Acid Receptor, Lysophosphatidic,Acid Receptors, Lysophosphatidic,Edg 4 Receptor,Edg 7 Receptor,LPA 1 Receptor,Receptor, Edg-4,Receptor, Edg-7,Receptor, LPA,Receptor, LPA1,Receptor, LPA2,Receptor, LPA3,Receptor, edg-2,Receptor, vzg-1,Receptors, LPA,edg 2 Receptor,vzg 1 Receptor
D018270 Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST. Carcinoma, Infiltrating Duct,Carcinoma, Invasive Ductal, Breast,Carcinoma, Mammary Ductal,Invasive Ductal Carcinoma, Breast,Mammary Ductal Carcinoma,Carcinomas, Infiltrating Duct,Carcinomas, Mammary Ductal,Mammary Ductal Carcinomas

Related Publications

Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma.
March 2013, The Journal of surgical research,
Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma.
April 2013, Journal of pineal research,
Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.
December 2011, Sao Paulo medical journal = Revista paulista de medicina,
Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Over-expression of NOTCH1 as a biomarker for invasive breast ductal carcinoma.
June 2016, 3 Biotech,
Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Human Epidermal Growth Factor Receptor 2-Subtype Invasive Ductal Carcinoma Recurring as Basal-Human Epidermal Growth Factor Receptor 2-Subtype Squamous Cell Carcinoma.
September 2019, Journal of breast cancer,
Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression.
March 2011, Oncogene,
Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Nm23 protein expression in ductal in situ and invasive human breast carcinoma.
May 1993, Journal of the National Cancer Institute,
Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
March 2012, Breast cancer research : BCR,
Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Hsp-27 expression in invasive ductal breast carcinoma.
January 2012, Folia histochemica et cytobiologica,
Joji Kitayama, and Dai Shida, and Akihiro Sako, and Makoto Ishikawa, and Kotaro Hama, and Junken Aoki, and Hiroyuki Arai, and Hirokazu Nagawa
Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
February 2006, Breast cancer research and treatment,
Copied contents to your clipboard!